At Help Therapeutics, scientists use induced-pluripotent stem cell (iPSC) and mesenchymal stem cell (MSC) technologies to develop a new generation of universal cell therapy products to treat currently intractable diseases. We aim to lead the development of regenerative medicine, meet the most urgent clinical needs and reshape human health.


Unique Qualities of our Stem Cell R&D Platform


——   GMP Grade Cell Therapy Product Manufacturing   ——

Help Therapeutics established the first GMP compliant induced-pluripotent stem cell product manufacturing system in China. All products passed stringent quality control tests before release.


——   Oriented Stem Cell Differentiation Technologies   —— 

Our scientists developed efficient differentiation technologies enabling the derivation of highly pure cardiomyocytes, nerve cells and other cell types from iPSCs and MSCs. These technologies were further transformed into standardized, scalable cell product manufacturing procedures.


——   Clinical Translation of Stem Cell Therapy   ——

We forged in-depth collaboration with renowned medical professionals from multiple top-notch hospitals and medical institutes. Clinical studies based on these collaborations critically accelerated bench-to-bedside translation of latest Stem Cell Technologies.


——   Coordination of Regional Stem Cell Research   ——

Help Therapeutics constructed and operates the first and only National level, Government accredited induced-pluripotent stem cell bank, the Chinese Bank of induced-pluripotent stem cells (CBiPS). Housing hundreds of iPSC lines derived from healthy donors and rare disease patients, CBiPS represents the largest iPSC repository in China and coordinates iPSC orientated research involving cell therapy, disease modeling, drug screening and safety evaluation.